



## Leveraging EHR Capabilities to Support ORZEYFUL<sup>®</sup> (oveporexton) for the Treatment of Narcolepsy in Clinical Workflows

How EHR capabilities can support prescribing workflows and medication visibility for ORZEYFUL

EHR=electronic health record.

### INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in patients 16 years and older.

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients:

- Taking strong CYP3A inhibitors
- With severe hepatic impairment (Child-Pugh C)

Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).





## About This Guide

This instructional guide provides information to assist with updating the EHR to support ORZEYFUL® (oveporexton), a new treatment for narcolepsy type 1. It includes examples and steps to help healthcare providers include ORZEYFUL in prescribing workflow capabilities.

This resource is meant to serve as summary information only and should not replace detailed instructions provided to you by your internal or external EHR support resources. Screen images shown within represent hypothetical EHR screens. Takeda makes no claims or warranties about the applicability or appropriateness of this information.

This guide is meant to provide guidance for you, your office manager, your EHR champion, and EHR team staff. It provides examples for discussion purposes only, does not constitute guidance or medical advice for treatment, and does not represent all workflows for implementation. It is ultimately the responsibility of the healthcare professional to select a treatment based on their independent medical judgment and the need of each individual patient.

The user is solely responsible for the implementation, testing, and monitoring to ensure proper orientation in the EHR system.

## IMPORTANT SAFETY INFORMATION (cont.)

### WARNINGS AND PRECAUTIONS

**Discontinuation of ORZEYFUL:** Discontinuation effects of oveporexton have not been systematically evaluated in controlled clinical studies. Therefore, it is recommended to monitor patients following discontinuation of therapy.

*Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).*

**Orzeyful**<sup>®</sup>  
oveporexton tablets(x)



# Table of Contents

About This Guide.....	2
Why This Matters.....	3
<b>Favorites/Preferences.....</b>	<b>4</b>
ORZEYFUL® (oveporexton) Order Sets .....	6
Alerts .....	7
Patient Education .....	8

## Why This Matters



symptoms can interfere with daily routines, school or work responsibilities, safety, and overall quality of life.<sup>2</sup>

As new treatment options become available, health systems may need to consider how those therapies are incorporated into existing clinical and EHR workflows. Updating the EHR workflow may help support consistency in patient care for the treatment of narcolepsy.

### IMPORTANT SAFETY INFORMATION (cont.)

#### ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) reported in Phase 3 studies with ORZEYFUL were insomnia, pollakiuria, micturition urgency, and salivary hypersecretion.

*Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).*



ABOUT THIS GUIDE

WHY THIS MATTERS

FAVORITES/  
PREFERENCES

ORDER SETS

ALERTS

PATIENT EDUCATION



## Favorites/Preferences



Adding ORZEYFUL® (oveporexton) as a Favorite or Preference may help streamline the prescribing workflow. Favorites/Preferences may improve efficiency, support consistency, and make the desired option more readily accessible at the point of care.

Most EHRs allow prescribers to save frequently prescribed medications, which are stored as a separate list for quicker access. These entries include complete prescription details such as medication name, strength, form, quantity, unit of measure, patient instructions, and number of refills. Some EHRs automatically create a list of favorites based on frequently written prescriptions.

Depending on the organization's configuration and governance model, Favorites/Preferences may be managed at the individual user level, team level, or broader system level.

The ability and process for saving products as a Favorite/Preference may differ by organization. Some EHRs enable the ability to save Favorites/Preferences at the physician and practice level. The process for saving a prescription as a Favorite/Preference varies between each EHR system.

### Adding ORZEYFUL® (oveporexton) as a Favorite

These instructions provide general guidance that informs saving ORZEYFUL as a Favorite.

1. Navigate to the Ordering area and open the module where orders are placed.
2. Search for and select ORZEYFUL.
3. Open ORZEYFUL details and mark it as a Favorite. Look for and select the option that supports marking it as a Favorite, such as:
  - a. Star ★ icon
  - b. "Add to Favorites"
  - c. "Save as Favorite"
  - d. "Add to My List" or
  - e. "Pin"
4. If prompted, confirm saving ORZEYFUL as a medication Favorite.

**Note:** *If applicable, this process can be repeated for multiple dosage strengths.*

## IMPORTANT SAFETY INFORMATION (cont.)

### DRUG INTERACTIONS

- Concomitant use with strong or moderate CYP3A inhibitors increases oveporexton exposures.
- Concomitant use of strong and moderate CYP3A inducers can increase oveporexton metabolism and therefore can decrease plasma levels of oveporexton.

**Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).**

**Orzeyful**<sup>®</sup>  
oveporexton tablets(x)



eClinicalWorks allows HCPs to save medications as favorites by clicking the ★ icon. athenaOne® EHR cannot explicitly save prescriptions as Favorites. It does, however, save a list of the most Frequently Written Prescriptions.

Information needed to save a product as a favorite may include:

- Medication name, strength, and form
- Quantity
- Unit of measure
- Patient instructions
- Number of refills
- Dispense as written (DAW)
- Specialty pharmacy pre-selection

Medication Summary										
Add New Rx										
Add New Order										
ORZEYFUL		<	>	☆	▼	?	Rx Eligibility	PDMP	Add Custom	New
D	✎	★	?	Strength	Take	Route	Frequency	Duration	Dispense	Refill
		★		2 mg	One tablet	Oral	BID			

Example of adding Orzeyful as a favorite

## IMPORTANT SAFETY INFORMATION (cont.)


### PREGNANCY AND LACTATION

- 1.1 There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to ORZEYFUL during pregnancy. Patients should be encouraged to enroll in the ORZEYFUL pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call [1-800-XXX-XXXX].
  - There are no available data on the use of ORZEYFUL during pregnancy. There are no data available on the presence of oreporexton in human milk. Animal studies indicate that oreporexton was present in the milk of lactating rats.

Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).



# ORZEYFUL® (overporexton) Order Sets



1. Consider which Order Set is to be updated, and which orders are to be included.
2. Search for and select the appropriate Order to be updated.
3. Add the appropriate medication to include all relevant doses, to the Order Set; for example, ORZEYFUL 2 mg tablet.
4. Test and save the Order Set once finished.

Incorporating specialty pharmacy into the ORZEYFUL Order Set build requires the following information:

- Approved specialty pharmacy list
- Routing logic, eg [add Takeda hub link if it's being used for Orzeyful]
- Documentation requirements
- Task triggers

**Manage My Order Sets**

Ask on Order Entry (AOE) questions and answers will auto-populate

**Add Order Set**

Order Set Name: ORZEYFUL 2 mg tablet **2**

Ordering: [input field]

Diagnoses: [input field]

Quickpicks Search Diagnosis Order Set

no items found

Selected diagnoses: None selected

Diagnoses and Orders Detail

**No Diagnosis**

Add Orders Order Set Medication Lab Imaging

Quickpicks: Patient Hi **3** Search: ORZEYFUL 2 mg tablet

no items found N/A

Example of adding an ORZEYFUL dose to an Order Set



eClinicalWorks and athenaOne® use the term Order Sets to group orderable items.

## IMPORTANT SAFETY INFORMATION (cont.)

### DRUG ABUSE AND DEPENDENCE

ORZEYFUL contains the active ingredient overporexton. (Controlled substance schedule to be determined after review by the Drug Enforcement Administration.)

Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).

**Orzeyful**  
oveporexton tablets(x)



# Alerts

EHRs include functionality to trigger a reminder for healthcare providers.

Alerts, also known as reminders or notifications, are EHR-based prompts that draw a user's attention to information or a potential next step in care. These prompts may be actionable, encouraging the user to complete a task (eg, placing an order or completing a follow-up), or informational, where no immediate action is required.

Depending on configuration and urgency, alerts may appear during a patient encounter or be delivered asynchronously, such as through a clinician inbox or task list, without interrupting in-workflow documentation.

EHRs refer to alerts and reminders by different names and sometimes use the terms synonymously.




**eClinicalWorks and athenaOne® have Alert functionality.**

**In eClinicalWorks, Alerts may surface within the patient chart or visit workflow, as tasks, messages, or dashboard indicators. They may also surface as inbox-based messages. Only users with appropriate permissions are able to set up Alerts.**

**In athenaOne, Alerts are commonly implemented through clinical decision support notifications or order-associated alerts. They are preconfigured in the Quality Module by athenaOne and cannot be created or edited by practice staff. To request an Alert, log a request with athenaOne customer support.**

Clearly defined alert criteria support creating and requesting alerts. Well-designed alert criteria ensure alerts



## Specialty Pharmacy Alert

ORZEYFUL® (oveporexton) requires dispensing through a specialty pharmacy. An alert may be useful to prompt the provider to appropriately route the prescription at the point of prescribing.

Criteria to support creating an alert may include:

1. Who the alert applies to, for example, patients with narcolepsy (ICD-10 G47.41) prescribed ORZEYFUL.
2. What triggers the alert, for example, ORZEYFUL order pending.
3. Type of alert, for example interruptive or non-interruptive.
4. What message should display within the alert, for example, An ORZEYFUL prescription requires selection of a specialty pharmacy.
5. What action should be taken, for example, view ORZEYFUL specialty pharmacy list.

## INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in patients 16 years and older.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients:

- Taking strong CYP3A inhibitors
- With severe hepatic impairment (Child-Pugh C)

**Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).**

**Orzeyful®**  
oveporexton tablets (x)



# Patient Education

Patient education resources within the EHR may help healthcare providers and staff share relevant information more efficiently during treatment discussions and follow-up. Making approved materials easier to access within workflow can support patient understanding, reduce extra administrative steps, and promote more consistent communication across the care team.

Depending on system capabilities and workflow preferences, these resources may be linked, embedded, or surfaced in ways that help healthcare providers and staff access them at the point of care.

When submitting a request to include ORZEYFUL® (oveporexton) patient education resources as Clinical References, consider including the following information along with the document and/or a link to the resource.

Once the health system has decided which patient resources to add within an EHR workflow, a request should be made to the health system's IT team including the following details.

## What to Request

Information	Details to include
Name or Title of Resource	For example, ORZEYFUL Information
Contents	Links to resources to include
Access Level	Define access, such as department-specific, facility-level, or provider-specific access
Method(s) of Delivery to the Patient	<ul style="list-style-type: none"> <li>As a handout to print and hand to the patient</li> <li>Available to send via patient portal</li> </ul>
Define the Audience for the Document	Patients interested in learning more about treatment with ORZEYFUL
Methods of Use	<ul style="list-style-type: none"> <li>Patient-facing to use in discussion with healthcare provider</li> <li>Added to post-visit summaries</li> <li>Send to patient via patient portal</li> </ul>
Specify How Users Will Access the Document	<ul style="list-style-type: none"> <li>Via reference link</li> <li>Other functionality</li> </ul>
Optional Hyperlink (Enabling Patient Access to External Information)	<ul style="list-style-type: none"> <li>ORZEYFUL patient website link [hyperlink when available]</li> </ul>



eClinicalWorks typically supports education delivery through custom documents, clinical documentation, and patient portal distribution rather than structured education orders.

In athenaOne®, patient education is often implemented as a distinct, orderable item, often referred to as an Education Info Order or education-related order. This may be configured to appear alongside orders for medications, labs, and other orderable items in the encounter.

## IMPORTANT SAFETY INFORMATION (cont.)

### WARNINGS AND PRECAUTIONS

**Discontinuation of ORZEYFUL:** Discontinuation effects of oveporexton have not been systematically evaluated in controlled clinical studies. Therefore, it is recommended to monitor patients following discontinuation of therapy.

Please see additional Important Safety Information on page 9 and click for [full Prescribing Information](#).



ABOUT THIS GUIDE

WHY THIS MATTERS

FAVORITES/  
PREFERENCES

ORDER SETS

ALERTS

PATIENT EDUCATION



## INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in patients 16 years and older.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients:

- Taking strong CYP3A inhibitors
- With severe hepatic impairment (Child-Pugh C)

### WARNINGS AND PRECAUTIONS

**Discontinuation of ORZEYFUL:** Discontinuation effects of oreporexton have not been systematically evaluated in controlled clinical studies. Therefore, it is recommended to monitor patients following discontinuation of therapy.

### ADVERSE REACTIONS

The most common adverse reactions (incidence  $\geq 5\%$  and greater than placebo) reported in Phase 3 studies with ORZEYFUL were insomnia, pollakiuria, micturition urgency, and salivary hypersecretion.

### DRUG INTERACTIONS

- Concomitant use with strong or moderate CYP3A inhibitors increases oreporexton exposures.
- Concomitant use of strong and moderate CYP3A inducers can increase oreporexton metabolism and therefore can decrease plasma levels of oreporexton.

### PREGNANCY AND LACTATION

- 1.1 There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to ORZEYFUL during pregnancy. Patients should be encouraged to enroll in the ORZEYFUL pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call [1-800-XXX-XXXX].
- There are no available data on the use of ORZEYFUL during pregnancy. There are no data available on the presence of oreporexton in human milk. Animal studies indicate that oreporexton was present in the milk of lactating rats.

### DRUG ABUSE AND DEPENDENCE

ORZEYFUL contains the active ingredient oreporexton. (Controlled substance schedule to be determined after review by the Drug Enforcement Administration.)

Please see [full Prescribing Information](#).

**Orzeyful**<sup>®</sup>  
oveporexton tablets(x)



ABOUT THIS GUIDE

WHY THIS MATTERS


FAVORITES/  
PREFERENCES

ORDER SETS

ALERTS

PATIENT EDUCATION



**References:**  ~~National Institute of Neurological Disorders and Stroke. *Narcolepsy*. Updated March 13, 2026. <https://www.ninds.nih.gov/health-information/disorders/narcolepsy> Accessed April 27, 2026.~~ **2.** Slowik JM, Collen JF, Yow AG. *Narcolepsy*. StatPearls Publishing; 2023. <https://www.ncbi.nlm.nih.gov/books/NBK459236/> Accessed April 27, 2026.

©2026 Takeda Pharmaceuticals U.S.A., Inc.  
 500 Kendall Street, Cambridge, MA 02142.  
 1-877-TAKEDA-7 (1-877-825-3327).  
 All rights reserved.

 TAKEDA and the  are registered trademarks of Takeda Pharmaceutical Company Limited.

All other trademarks are the property of their respective owners.

US-OVE-0375 05/26

**Orzeyful**<sup>®</sup>  
 oveporexton tablets(x)